Journal article
Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn’s disease patients
Abstract
BACKGROUND: Many Crohn's disease patients treated with anti-tumor necrosis factor (TNF) therapies suffer from loss of response over time and require dose escalation. The aim of this study was to evaluate the efficacy and safety of treating anti-TNF experienced Crohn's disease patients with higher maintenance regimens of adalimumab.
METHODS: In a retrospective observational study, Crohn's disease patients receiving adalimumab were categorized …
Authors
Greener T; Boland K; Milgrom R; Ben-Bassat O; Steinhart AH; Silverberg MS; Narula N
Journal
European Journal of Gastroenterology & Hepatology, Vol. 33, No. 10, pp. 1274–1279
Publisher
Wolters Kluwer
Publication Date
October 2021
DOI
10.1097/meg.0000000000002250
ISSN
0954-691X